Loading

IPOs Are Starting to Come Back: Are You Ready?

June 05, 2024
Breakout Session
Business Development and Finance
29AB
Many of the macroeconomic challenges that halted biotech IPO activity in 2022 and 2023 have begun to subside and the capital markets are expected to continue improving. While biotech IPOs might take a little while to get back to pre-pandemic levels, there's reason to be optimistic especially since the Fed is poised to lower rates in the second half of 2024. Our panel will dive into lessons learned from past IPOs and how early-stage biotech’s can avoid common pitfalls.
Speakers
Rich Ramko, CPA
Partner, US Biotech Leader
EY (Ernst & Young)
Speakers
Arvind Kush
CFO
RayzeBio
Steven Spector
Executive Vice President, Head of Business Development and General Counsel
Longboard Pharma
Kristin VanderPas
Partner
Cooley
Brad Wolff, MBA
Senior Managing Director |Global Advisory | Strategic Advisory | Mergers and Acquisition
Evercore
Back to Session List

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS